Older adults with questionable cognitive impairment exposed to anticholinergics demonstrated higher global cognitive scores compared to those not exposed to anticholinergics, according to a study published in Drugs & Aging.
Vertex announced that the Food and Drug Administration (FDA) has approved Orkambi (lumacaftor and ivacaftor) tablets for use in children with cystic fibrosis aged 6-11 years who have 2 copies of the F508del mutation.
A systematic review and meta-analysis published in the journal International Clinical Psychopharmacology found that pregabalin was superior to placebo for the amelioration of generalized anxiety disorder (GAD) symptoms.
Amgen announced positive top-line results from their Phase 3 trial ARISE, evaluating erenumab (AMG 334) for safety and efficacy in preventing migraines.
AstraZeneca announced that the Food and Drug Administration (FDA) has approved cobas EGFR Mutation Test v2, a companion diagnostic for Tagrisso (osimertinib).